Tarsus CEO sells 10,000 shares around $90
Tarsus Pharmaceuticals’ CEO, president and board chair reported 10,000 indirect share sales under a Rule 10b5-1 plan while retaining a direct stake of 33,421 shares.
Rhea-AI Filing Summary
Tarsus Pharmaceuticals, Inc. (TARS) reported that President, CEO and Board Chair Bobak R. Azamian, through the Bobak Azamian Living Trust, sold a total of 10,000 shares of common stock on September 4, 2026 in transactions reported as sales in the open market or in private transactions. The sales were executed under an automatic Rule 10b5-1 trading plan adopted on December 9, 2025, at weighted average prices of about $90.27 and $91.27 per share, with individual trades in ranges from $90.00 to $90.91 and from $91.06 to $91.45. Following these transactions, he is reported to hold 33,421 shares of common stock directly.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Net Seller: 10,000 shares
Net Sell
3 txns
Insider
Azamian Bobak R.
Role
President/CEO and Board Chair
Sold
10,000 shs ($906K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2, F3 | 7,100 | $90.27 | $641K |
| Sale | Common Stock F1, F4, F3 | 2,900 | $91.27 | $265K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 827,991 shares (Indirect, By the Bobak Azamian Living Trust established April 16, 2018);
Common Stock — 33,421 shares (Direct)
Footnotes (4)
- F1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025.
- F2. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $90.00 to $90.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
- F4. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $91.06 to $91.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Shares sold (total): 10,000 shares
Shares sold in first trade: 7,100 shares
Shares sold in second trade: 2,900 shares
+4 more
7 metrics
Shares sold (total)
10,000 shares
Common stock sales on September 4, 2026 by the Bobak Azamian Living Trust
Shares sold in first trade
7,100 shares
Weighted average price about $90.27; individual trades between $90.00 and $90.91
Shares sold in second trade
2,900 shares
Weighted average price about $91.27; individual trades between $91.06 and $91.45
Weighted average sale price (first block)
$90.27 per share
Sale of 7,100 shares on September 4, 2026
Weighted average sale price (second block)
$91.27 per share
Sale of 2,900 shares on September 4, 2026
Remaining direct holdings
33,421 shares
Directly owned common stock after transactions on September 4, 2026
Rule 10b5-1 plan adoption date
December 9, 2025
Automatic trading plan governing the reported sales
Key Terms
Rule 10b5-1 trading plan, weighted average price, dispositive power
3 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
dispositive power financial
"and has voting and dispositive power with respect to these shares."
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
FAQ
What insider transaction did TARS report for Bobak Azamian on this Form 4?
The filing reports that Bobak R. Azamian, Tarsus Pharmaceuticals’ president, CEO and board chair, sold 10,000 shares of TARS common stock on September 4, 2026 through transactions reported as open market or private sales executed by his living trust.
Were the TARS insider sales made under a Rule 10b5-1 trading plan?
Yes. The sales were effected under an automatic Rule 10b5-1 trading plan that Bobak R. Azamian adopted on December 9, 2025, as disclosed in the footnotes to the Form 4.
AI-generated analysis. How Rhea-AI works. Not financial advice.
